Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical TrialRobin K. Avery, Catherine Cordonnier, Rafael F. Duarte et al.|Clinical Infectious Diseases|2021Cited by 299
Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections ForumPer Ljungman, Dana G. Wolf, Roy F. Chemaly et al.|Clinical Infectious Diseases|2024Cited by 145
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant RecipientsSunwen Chou, Martha Fournier, Sophie Alain et al.|The Journal of Infectious Diseases|2023Cited by 77